References
- Smith WR, Scherer M. Sickle-cell pain: advances in epidemiology and etiology. Am. Soc. Hematol. Educ. Program409–415 (2010).
- Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin33(1), 1–16 (2009).
- Davis H, Schoendorf KC, Gergen PJ, Moore RM Jr. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am. J. Public Health87(8), 1317–1322 (1997).
- Platt OS, Thorington BD, Brambilla DJ et al. Pain in sickle cell disease. rates and risk factors. N. Engl. J. Med.325, 11–16 (1991).
- Smith WR, Penberthy LT, Bovbjerg VE et al. Daily assessment of pain in adults with sickle cell disease. Ann. Intern. Med.148, 94–101 (2008).
- Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA303(13), 1288–1294 (2010).
- Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am. J. Hematol.79, 17–25 (2005).
- Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br. J. Haematol.144(5), 782–788 (2009).
- Field JJ, Knight-Perry JE, DeBaun MR. Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. Curr. Opin. Hematol.16(3), 173–178 (2009).
- Dampier C, Setty BN, Eggleston B, Brodecki D, O’Neal P, Stuart M. Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. J. Pediatr. Hematol. Oncol.26(12), 785–790 (2004).
- Hebbel RP, Vercellotti G, Nath KA. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc. Hematol. Disord. Drug Targets9(4), 271–292 (2009).
- Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood116(10), 1779–1786 (2010).
- Gibbs WJ, Hagemann TM. Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann. Pharmacother.38(2), 320–324 (2004).
- Vandy Black L, Smith WR. Evidence-based mini-review: are systemic corticosteroids an effective treatment for acute pain in sickle cell disease? Hematol. Am. Soc. Hematol. Educ. Program416–417 (2010).
- Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. life expectancy and risk factors for early death. N. Engl. J. Med.330, 1639–1644 (1994).
- Woolf CJ, American College of Physicians, American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med.140(6), 441–451 (2004).
- Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum.46, 1333–1343 (2002).
- Wilkie DJ, Molokie R, Boyd-Seal D et al. Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J. Natl Med. Assoc.102(1), 18–27 (2010).
- Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med.332(20), 1317–1322 (1995).
Website
- US FDA Office of Orphan Products Development. L-glutamine therapy for sickle cell anemia and sickle β0 thalassemia. Emmaus Medical, Inc. ClinicalTrials.gov identifier: NCT00125788 http://clinicaltrials.gov/ct2/show/NCT00586209